A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous Administration of Secukinumab (AIN457) in Patients With Asthma Not Adequately Controlled With Inhaled Corticosteroids and Long Acting Beta-agonists
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Secukinumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Novartis
- 19 Nov 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 14 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 20 Sep 2013 Planned end date changed from 1 May 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.